DE2903579A1 - Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel - Google Patents

Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel

Info

Publication number
DE2903579A1
DE2903579A1 DE19792903579 DE2903579A DE2903579A1 DE 2903579 A1 DE2903579 A1 DE 2903579A1 DE 19792903579 DE19792903579 DE 19792903579 DE 2903579 A DE2903579 A DE 2903579A DE 2903579 A1 DE2903579 A1 DE 2903579A1
Authority
DE
Germany
Prior art keywords
carnitine
acetylcarnitine
acetyl
treatment
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19792903579
Other languages
German (de)
English (en)
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT4790078A external-priority patent/IT1104165B/it
Priority claimed from IT4935478A external-priority patent/IT1156740B/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE2903579A1 publication Critical patent/DE2903579A1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE19792903579 1978-02-03 1979-01-31 Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel Ceased DE2903579A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT4790078A IT1104165B (it) 1978-02-03 1978-02-03 Nuova applicazione terapeutica della carnitina della acetil-carnitina e di altri derivati acilati della carnitina
IT4935478A IT1156740B (it) 1978-05-15 1978-05-15 Applicazione terapeutica della acetil-carnitina e di altri derivati acilati della carnitina

Publications (1)

Publication Number Publication Date
DE2903579A1 true DE2903579A1 (de) 1979-08-09

Family

ID=26329245

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19792903579 Ceased DE2903579A1 (de) 1978-02-03 1979-01-31 Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel

Country Status (6)

Country Link
US (1) US4268524A (cg-RX-API-DMAC7.html)
JP (1) JPS54113442A (cg-RX-API-DMAC7.html)
CH (1) CH640413A5 (cg-RX-API-DMAC7.html)
DE (1) DE2903579A1 (cg-RX-API-DMAC7.html)
GB (1) GB2013496B (cg-RX-API-DMAC7.html)
NL (1) NL7900872A (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3015636A1 (de) * 1979-04-23 1980-11-06 Sigma Tau Ind Farmaceuti Ester von acyl-carnitinen, verfahren zu deren herstellung und diese enthaltende arzneimittel
FR2477536A1 (fr) * 1980-03-06 1981-09-11 Sigma Tau Ind Farmaceuti Nouveaux derives acyles de carnitine, procede de preparation de ces derives et leur utilisation therapeutique
DE3339052A1 (de) * 1982-10-29 1984-05-03 Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma Pharmazeutisches praeparat zur verbesserung der biochemischen und verhaltens-parameter bei senilitaet

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1143214B (it) * 1981-07-09 1986-10-22 Sigma Tau Ind Farmaceuti Acil derivato della carnitina quale immunomodulatore
IT1150751B (it) * 1982-04-01 1986-12-17 Montedison Spa Composizioni acaricide
FR2619007B1 (fr) * 1987-08-07 1990-09-28 Dermatologiques Et Preparations cosmetiques a action lipolytique
FR2633929B2 (fr) * 1987-09-25 1995-05-24 Picardie Universite Derives non toxiques de l'acide n-butyrique, presentant des actions therapeutiques retardees
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
IT1231944B (it) * 1989-05-05 1992-01-16 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina
FR2654619B1 (fr) * 1989-11-23 1992-01-31 Sederma Sa Utilisation en cosmetique de composes destines a optimiser la penetration des principes actifs.
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
ITRM20040307A1 (it) 2004-06-23 2004-09-23 Sigma Tau Ind Farmaceuti Confezione per almeno due prodotti differenti da vendere e utilizzare insieme.
JP2006347935A (ja) * 2005-06-15 2006-12-28 Masanori Ogata 炎症性サイトカインの産生が関与する疾患の予防及び／又は治療のための医薬
US8003683B2 (en) * 2005-11-11 2011-08-23 Signature R&D Holdings, Llc Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
DE2846335A1 (de) * 1977-11-03 1979-05-10 Sigma Tau Ind Farmaceuti Derivate des d,l- bzw. l-carnitins sowie diese enthaltende arzneimittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968241A (en) * 1972-11-06 1976-07-06 Defelice Stephen L Method of treating cardiac arrhythmias and of improving myocardial contractility and systolic rhythm with carnitive or a pharmaceutically acceptable salt thereof
US4032641A (en) * 1976-06-09 1977-06-28 Tanabe Seiyaku Co., Ltd. Nicotinoyl carnitine derivatives
AU518617B2 (en) * 1977-04-29 1981-10-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Therapeutic application of acetyl-d, 1-carnitine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
DE2846335A1 (de) * 1977-11-03 1979-05-10 Sigma Tau Ind Farmaceuti Derivate des d,l- bzw. l-carnitins sowie diese enthaltende arzneimittel

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FREDRICKSON, D.S. et.al.: New Engl. J. Med. 276, (1968), S. 34-44 *
FURMANN, R.H. et.al.: Am. J. Clin. Nutr. 9 (1961), S. 73-102 *
US-B.: TIENGO, T. et.al.: Int. Conference on Atheroselerosis, Milano, Nov. 1977, Ed. L.A. Carlson et.al., Raven Press, New York 1978, S. 327-331 *
US-Z.: GORDON, T. et.al.: Am. J. Med., Vol. 62, (May 1977) S. 707-714 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3015636A1 (de) * 1979-04-23 1980-11-06 Sigma Tau Ind Farmaceuti Ester von acyl-carnitinen, verfahren zu deren herstellung und diese enthaltende arzneimittel
FR2477536A1 (fr) * 1980-03-06 1981-09-11 Sigma Tau Ind Farmaceuti Nouveaux derives acyles de carnitine, procede de preparation de ces derives et leur utilisation therapeutique
DE3339052A1 (de) * 1982-10-29 1984-05-03 Sigma-Tau S.p.A. Industrie Farmaceutiche Riunite, 00144 Roma Pharmazeutisches praeparat zur verbesserung der biochemischen und verhaltens-parameter bei senilitaet

Also Published As

Publication number Publication date
GB2013496A (en) 1979-08-15
JPS649289B2 (cg-RX-API-DMAC7.html) 1989-02-16
GB2013496B (en) 1983-01-12
CH640413A5 (it) 1984-01-13
JPS54113442A (en) 1979-09-05
US4268524A (en) 1981-05-19
NL7900872A (nl) 1979-08-07

Similar Documents

Publication Publication Date Title
DE2903579A1 (de) Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
DE2903558C2 (de) Verwendung von L-Carnitin
DE69618158T2 (de) Pharmazeutische Zusammensetzung enthaltend ein Alkanoyl-L-Carnitin in Kombination mit einer polyungesättigten Fettsäure der Omega-3-Serie zur Verhütung und Behandlung von Störungen des Fettstoffwechsels
DE60212786T2 (de) Verwendung mehrfach ungesättigter Fettsäuren zur primären Prävention kardiovaskulärer Ereignisse
DE69629273T2 (de) Zusammensetzungen enthaltend Propionyl-L-Carnitine und Hydroxyzitronensäure oder Pantothensäure
EP0607231B1 (de) Verwendung einer emulsion, zur herstellung eines arzneimittels zur i.v.-verabreichung zur behandlung von hauterkrankungen
DE69911441T2 (de) Verwendung von carnitinen und resveratrol zur herstellung einer zusammensetzung zur verhinderung oder behandlung von zerebralenerkrankungen verursacht durch alterung und verwendung neurotoxischer mittel
DE69624699T2 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE2911670A1 (de) Arzneimittel zur therapeutischen behandlung von peripheren vaskularen erkrankungen
DE69328618T2 (de) Medikamente auf der Basis von Docosahexaensäure, als Plättchenaggregationshemmer und gegen cerebralen Mangel an Fettsäuren, und Verfahren zur Herstellung.
DE69612755T2 (de) Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
EP0282696B1 (de) Verwendung von Pyridoxin-Derivaten bei der Prophylaxe und Therapie von Hyperlipidämien und Atherosklerose
DE69733089T2 (de) Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin
DE4116004C2 (de) Nährstoffzubereitung
EP0185210A2 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE69826674T2 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
DE3726945A1 (de) L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE3000139A1 (de) Die verwendung von glyzerinphosphorylderivaten in der therapie der dislipaemie, der hepatitis und vergleichgeeignete pharmazeutische kompositionen
DE60207442T2 (de) VERWENDUNG EINER KOMBINATIONSZUSAMMENSETZUNG BESTEHEND AUS PROPIONYL L-CARNITIN UND WEITEREn WIRKSTOFFEn ZUR BEHANDLUNG DER EREKTILEN DYSFUNKTION
DE2445801A1 (de) Arzneimittel zur behandlung von diabetischer ketoacidose
DE3234537A1 (de) Arzneimittel zur behandlung kardiovaskulaerer erkrankungen
DE2335216A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung
DE2743704C2 (de) L- oder DL-Phenylglycine enthaltende Arzneimittel
DE2131679A1 (de) 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8131 Rejection